Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is a promising biopharmaceutical company utilizing precision medicine to develop anti-cancer treatments, with a current focus on stenoparib for ovarian cancer. Despite potential risks such as balance sheet issues and competition, Allarity has a strong pipeline and the potential to bring valuable treatments to patients with high unmet medical needs, making for a positive long-term outlook for investors.

Bears say

Allarity Therapeutics is a clinical-stage pharmaceutical company with a negative outlook due to its minimal revenue generation, high cash burn rate, and lack of guidance or consensus estimates. Its main drug, Stenoparib, is still in the development phase, and the clinical data has not shown enough promise to justify the large market potential for ovarian cancer and the highly competitive PARP inhibitor market. The company's high risk and lack of strong results make it an unattractive investment opportunity.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.